Bausch + Lomb, Corporation’s consumer eye care and vision health lines did their part in the latest quarter to help meet CEO Brent Saunders’ expectation that the firm isn’t seen as a pharmaceutical company.
The Canadian firm on 2 August reported Lumify eye drops, PreserVision and Ocuvite dietary supplements and other OTC drug or supplement brands accounted for 67% of its vision care business’s $646m in total sales, which accounted for well above half B+L’s total revenues just short
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?